Desmopressin for treatment of stroke patients on antiplatelet therapy
Research type
Research Study
Full title
Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH)
IRAS ID
233744
Contact name
Nikola Sprigg
Contact email
Sponsor organisation
University of Nottingham
Eudract number
2018-001904-12
Duration of Study in the UK
1 years, 8 months, 30 days
Research summary
Haemorrhagic stroke, an emergency caused by bleeding in the brain, often leads to death or long-term disability. A quarter of these patients are taking blood-thinning drugs (antiplatelet drugs, such as aspirin) because they are at risk of a heart attack or ischaemic stroke. Patients taking these drugs are more likely to die or be disabled if they have a haemorrhagic stroke. At present, there is no effective treatment for reversing their effects. Desmopressin is a drug which may reverse the effects of antiplatelet drugs and stop bleeding. We would like to run a large randomised trial to see if Desmopressin can reduce the number of people who die or are disabled after haemorrhagic stroke.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
18/EM/0184
Date of REC Opinion
22 Aug 2018
REC opinion
Further Information Favourable Opinion